BBIOBridgeBio Pharma, Inc.
Price
+25%1YEnd-of-day closes, not the intraday tick.
Survival is the story here: start there
Quality mixed, hard red flags, growing in the filings, the market undecided.
BridgeBio Pharma, Inc. is a commercial-stage, multi-product biopharmaceutical company organized around a portfolio operating model to discover, develop, and deliver medicines for patients with genetic diseases. We seek to translate advances in genetic science into therapies for patient populations with significant unmet medical needs. Since our founding 10 years ago, we have advanced multiple programs from discovery through regulatory approval and commercialization.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
BridgeBio Pharma, Inc. (BBIO) reported revenue of $244M in Q2 2026 (quarter ended Jun 30, 2026), up 120% from the same quarter a year earlier. That came with a gross margin of 94% and net loss of $156M. For the full year FY2025, revenue was $502M (+126% year on year) and net income −$733M. Its largest product in Q2 2026 was License Services And Royalty at $18M, 45% of the disclosed total, just ahead of Royalty at 40%. The next results filing is expected around Oct 28, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 31, 2026The Company expects its pricing commitment for its future medicines under its agreement with the U.S. government to exclude medicines approved exclusively for orphan indications.Other event · Form 8-K
- Aug 17, 2026On August 13, 2026, BridgeBio Pharma, Inc. (the “Company”) and KKR Genetic Disorder L.P. (the “Selling Stockholder”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with William Blair & Company, L.L.C., Goldman Sachs & Co. LLC and KKR Capital Markets LLC, as the representatives of the several …Material agreement entered · Form 8-K
- Aug 10, 2026BridgeBio Reports Second Quarter 2026.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $38.8MThe company’s own SEC segment disclosure.
- License Services And Royalty$17.6M45%
- Royalty$15.4M40%
- License And Service$5.8M15%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.